299. Cystic fibrosis Clinical trials / Disease details


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-013660-39-FR
(EUCTR)
10/09/200927/11/2009Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ®Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ® Mucoviscidose
MedDRA version: 12.0;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Product Name: Nebcinal
INN or Proposed INN: tobramycine
Trade Name: Tobi
Product Name: Tobi
INN or Proposed INN: tobramycine
Erempharma SASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
2EUCTR2005-002035-28-LT
(EUCTR)
19/09/200524/08/2005A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) SubjectsA Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects pulmonary P aeruginosa infection in patient with cystic fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Product Name: Tobramycin Inhalation Powder
Product Code: TIP
INN or Proposed INN: Tobramycine
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
220Phase 3Lithuania